34 filings
8-K
CLRB
Cellectar Biosciences Inc
19 Dec 19
Cellectar Biosciences to Present at Biotech Showcase 2020
4:03pm
8-K
CLRB
Cellectar Biosciences Inc
16 Dec 19
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
4:03pm
8-K
CLRB
Cellectar Biosciences Inc
9 Dec 19
Regulation FD Disclosure
4:01pm
8-K
CLRB
Cellectar Biosciences Inc
4 Dec 19
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
12:00am
8-K
CLRB
Cellectar Biosciences Inc
12 Nov 19
Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
8:33am
8-K
zqnov
30 Oct 19
Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4:01pm
8-K
5e5std5 2r
17 Oct 19
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
4:09pm
8-K
a0u1s7wxw9glj 9ym
15 Oct 19
Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
4:07pm
8-K
qr2cx h0id60we64
8 Oct 19
Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
4:01pm
8-K
7wfjaouf272lpw99hd
30 Sep 19
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
4:02pm
8-K
7fz1gn9b5a
24 Sep 19
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
4:25pm
8-K
bemtg4cyf
16 Sep 19
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
4:02pm
8-K
8s2sdm2eno9 mptsb9
10 Sep 19
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
4:42pm
8-K
t36r9j po76a0k97
4 Sep 19
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop
4:08pm
8-K
3xg7 2rvrnn5
15 Aug 19
Cellectar Appoints Dov Elefant as Chief Financial Officer
8:30am
8-K
46cxh
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
z4ia86qk1
12 Aug 19
Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
8:30am
8-K
j8176kae5cxbnkpr864y
9 Jul 19
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
4:05pm
8-K
ftu 6pzk3ftat
14 Jun 19
Departure of Directors or Certain Officers
4:04pm
8-K
hp0dsb3ys8ihuva0z
21 May 19
Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
4:20pm